Evogene (EVGN) Projected to Post Quarterly Earnings on Thursday

Evogene (NASDAQ:EVGN) is anticipated to release its Q3 2025 results before the market opens on Thursday, November 20th. Analysts expect Evogene to post earnings of ($0.41) per share and revenue of $0.65 million for the quarter. Interested persons can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Thursday, November 20, 2025 at 9:00 AM ET.

Evogene Price Performance

NASDAQ:EVGN opened at $1.25 on Thursday. The firm has a market cap of $6.71 million, a PE ratio of -0.56 and a beta of 1.50. The firm has a 50 day simple moving average of $1.23 and a 200-day simple moving average of $1.27. Evogene has a 1-year low of $0.95 and a 1-year high of $2.42.

Institutional Investors Weigh In On Evogene

A hedge fund recently raised its stake in Evogene stock. Jane Street Group LLC grew its holdings in Evogene Ltd. (NASDAQ:EVGN) by 58.0% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 33,732 shares of the biotechnology company’s stock after acquiring an additional 12,387 shares during the period. Jane Street Group LLC owned about 0.63% of Evogene worth $42,000 as of its most recent SEC filing. Institutional investors own 10.40% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Evogene in a research note on Wednesday, October 8th. Alliance Global Partners upgraded Evogene to a “strong-buy” rating in a research note on Monday, August 11th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Evogene presently has a consensus rating of “Moderate Buy” and a consensus price target of $3.50.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.